KCTD9 and colorectal carcinoma: In addition, CRC patients presenting with high KCTD9 expression in primary tumors showed significantly better outcomes in terms of OS and DSS (Fig. 2A, B), indicating the contribution of KCTD9 loss to patient outcomes.